A Phase 4 interventional study of Dexmedetomidine and Midazolam and Ketamine and Midazolam in Emergence Delirium, sponsored by Kasr El Aini Hospital. Recruiting at 1 site in Egypt. Open to participants aged 2 Years to 6 Years. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by Kasr El Aini Hospital · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies testing dexmedetomidine in Emergence Delirium — 31 open to participants now, 32 under way, 2 of them phase 3. Dexmedetomidine · Emergence Delirium.
Among the 83 studies testing dexmedetomidine in Emergence Delirium, this one is the 71st largest by planned enrollment, is one of 16 that started in 2026, is one of 31 in phase 4, reaches primary completion later than 18 of the 31 other live ones, and was the 70th registered.
753 studies on the registry are indexed under Emergence Delirium; 261 are open to participants now.
Browse Emergence Delirium studies →31 of the 83 studies testing dexmedetomidine in Emergence Delirium are open now, in 10 countries. Recruiting first, the newest first:
Pakistan Institute of Medical Sciences · Sites in Pakistan
Ages 2–12 · Healthy volunteers
Boston Children's Hospital · Sites in United States
Ages 1–12
Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital · Sites in Turkey
Ages 2–10
Bach Mai Hospital · Sites in Vietnam
Ages 18–65
Ain Shams University · Sites in Egypt
Ages 3–16
By country, each count listing its studies:
Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 141 Emergence Delirium studies recruiting now, 78 (55%) set no upper age limit and 43 (30%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.
This study: 2 Years to 6 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 13 · Phase 4 31
First in 2006; this study’s year is marked. 16 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 120 across 467 interventional studies indexed under Emergence Delirium.
Median enrollment 100 across the 83 interventional studies. Of the 38 that completed or were terminated, 10 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 83 have an industry lead sponsor. The 10 most frequent:
Kasr El Aini Hospital is the lead sponsor of 288 studies on the registry; 35 are open to participants now.
Kasr El Aini Hospital has 1 study filed under Emergence Delirium — fewer than ten, so there is no comparison to draw.
13 of the studies testing dexmedetomidine in Emergence Delirium that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07538284Phase 3Sixth Affiliated Hospital, Sun Yat-sen UniversityMInimizing Delirium With Nasal Dexmedetomidine-InducEd Sleep (MIDDIES) | 2026-12-31 |
| NCT07810556Phase 3Assiut UniversityIntrathecal Dexmedetomidine and Postoperative Delirium in Elderly Hip Fracture Surgery | 2027-10 |
| NCT07519863Ain Shams UniversityThe Effect of Dormicum-Ketamine Versus Dexmedetomidine on Emergence Delirium During Deep Sedation in Paediatric Burn Patients | 2026-11 |
| NCT07799311Pakistan Institute of Medical SciencesComparing the Efficacy of Propofol and Dexmedetomidine in Prevention of Emergence Agitation After Sevoflurane Anesthesia in Children | 2026-11-28 |
| NCT07601698Sohag UniversityDexmedetomidine vs Propofol-lidocaine Mixture in Preventing the Post Operative Emergence Agitation Following Sevoflurane Anasthesia | 2026-11-30 |
Add all 13 to your calendar (.ics) → With an account.
Among the 83 studies testing dexmedetomidine in Emergence Delirium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Fifty children undergoing heart catheterization without local anesthesia in the skin will be randomly divided into two groups.
Group DM (Dexmedetomidine + Midazolam) and Group KM (Ketamine + Midazolam)
Fifty children undergoing heart catheterization without local anesthesia in the skin will be randomly divided into two groups.
Group DM (Dexmedetomidine + Midazolam) will receive dexmedetomidine 1 µg/kg IV over 10 minutes and midazolam 0.1 mg/kg IV as a bolus concomitant with induction, followed by a continuous infusion of dexmedetomidine at 0.5 µg/kg/h and midazolam at 0.1 mg/kg/h for maintenance.
Group KM (Ketamine + Midazolam) will receive ketamine 1 mg/kg IV and midazolam 0.1 mg/kg IV as a bolus for induction, followed by a continuous infusion of ketamine at 1 mg/kg/h and midazolam at 0.1 mg/kg/h.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Children will receive Dexmedetomidine + Midazolam
Drug: Dexmedetomidine and Midazolam
Children will receive ketamine + Midazolam
Drug: Ketamine and Midazolam
Drug pages: DexmedetomidineStudies of DexmedetomidineDexmedetomidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · MidazolamStudies of MidazolamMidazolam pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Children will receive Dexamedetomedine and Midazolam
Also known as: Precedex and Dormicum
Drug pages: KetamineStudies of KetamineKetamine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · MidazolamStudies of MidazolamMidazolam pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Children will receive Ketamine and Midazolam
Also known as: katalar and Dormicum
Emergence delirium
Incidence of emergence delirium assessed using the Pediatric Anesthesia Emergence Delirium PAED scale. The scale consists of five behavioral items, each rated on a 5-point scale from 0 to 4(Eye contact, Purposefulness, Awareness, Restlessness, Inconsolability),Total scores range from 0 to 20.A PAED score ≥10 will be considered a clinically significant ED.
Time frame: 30 minutes post-anesthesia
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Dec 2026, 10 months after the start.
Of 50 non-industry phase 4 interventional studies under Emergence Delirium, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 33. This study's planned 10 months is below that.
Counting every sponsor, half of 50 studies reached it within 19 months; a quarter within 11 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dexmedetomidine · Midazolam · Ketamine